Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart for Injection in Adult-Onset Still's Disease (glucocorticoid tapering)
ChiCTR2600129224Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in adult-onset Still's disease (AOSD) comparing Experimental arm: Firsekibart with Control arm: placebo (2 arms). Primary endpoint: Disease remission at week 24 (DOR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on ChiCTR2600129224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129224.